A Two Day, Randomised, Single Blind, Parallel Group Trial of Repeat Doses of Intranasal RV568 in the Vienna Challenge Chamber in Subjects With Seasonal Allergic Rhinitis (SAR).
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2011
At a glance
- Drugs RV 568 (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- 03 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Nov 2010 New trial record